Trial Profile

A Multicenter, Double-blind, Placebo- and Active-Controlled Parallel-Group Evaluation of the Safety and Efficacy of Vilazodone in Pediatric Patients With Major Depressive Disorder

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 14 Sep 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Vilazodone (Primary) ; Fluoxetine
Indications Major depressive disorder
Focus Registrational; Therapeutic Use
Acronyms VLZ-MD-22
Sponsors AbbVie; Allergan; Forest Laboratories

Most Recent Events

22 Oct 2018 Status changed from recruiting to completed.
21 Feb 2018 Planned number of patients changed from 400 to 470.
21 Feb 2018 Planned End Date changed from 1 Jun 2017 to 8 Sep 2018.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com